Pre-Exposure Prophylaxis for Prevention of HIV

Tuesday, May 20, 2014, at 1 p.m. – 2 p.m.

An estimated 50,000 individuals become infected with the human immunodeficiency virus (HIV) in the United States annually. A new prevention strategy, Pre-exposure Prophylaxis (PrEP), is intended for high-risk populations to reduce their risk of becoming infected with HIV. PrEP includes daily medication and routine follow-up. When used consistently, PrEP is shown to reduce the risk of HIV infection. If delivered effectively and used in combination with other proven prevention methods, PrEP may play a significant role in helping to address the HIV epidemic in the United States.

This session of Grand Rounds will explore the opportunities for using PrEP as another tool to prevent the transmission of HIV and discuss the challenges to effective implementation that must be addressed to make PrEP a success.

Presented By

Walid Heneine, PhD 
Surveillance, Antiretroviral Prophylaxis and Drug Resistance Team Lead
Division of HIV/AIDS Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC
“HIV Pre-exposure Prophylaxis (PrEP) Preclinical Research in Animal Models”

Melanie Thompson, MD
Founder and Principal Investigator
AIDS Research Consortium of Atlanta
“Evolving Evidence from Clinical Trials of HIV Pre-Exposure Prophylaxis”

Dawn Smith, MD, MS, MPH 
Biomedical Interventions Activity Lead, Prevention with Negatives Team
Division of HIV/AIDS Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC
“Program and Policy Challenges for Delivery of PrEP”

Facilitated By

John Iskander, MD, MPH, Scientific Director, Public Health Grand Rounds
Phoebe Thorpe, MD, MPH, Deputy Scientific Director, Public Health Grand Rounds
Susan Laird, MSN, RN, Communications Manager, Public Health Grand Rounds

Additional Resources

• AIDSvu HIV data maps
• REMS clinician materials
• Medication Assistance Programs